Trivora

Quick links to important sections

Trivora

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trivora

Property Description
Active ingredients Levonorgestrel, Ethinyl Estradiol
Form Oral Tablet (Triphasic)
Pharmacological Class Estrogen/Progestin Combined Contraceptive
Common Use Prevention of Pregnancy (Contraception)
Origin Synthetic Hormones

What Type of Medicine is Trivora? (Identity and Classification)

Trivora is a prescription-only combination hormonal contraceptive (CHC), a systemic medication categorized under the pharmacological group of Estrogen/Progestin Combined Contraceptives. It is primarily used by women of reproductive potential for birth control. As a fixed-dose combination product, Trivora utilizes two synthetic sex hormones to achieve its primary general therapeutic purpose: preventing pregnancy. Levonorgestrel and Ethinyl Estradiol are recognized standards in contraceptive therapy. This combination, which is the same as that found in analogues like Triphasil and Enpresse, is clinically utilized for managing reproductive health.


Composition: The Ethinyl Estradiol and Levonorgestrel Combination

Trivora contains a combination of two synthetic active ingredients: Ethinyl Estradiol, which is the estrogen component, and Levonorgestrel, which is the progestin compound. The drug is prepared as an oral tablet and is characterized by its triphasic pill or sequential preparation. This unique structure is defined by its use of three distinct sequences of active tablets (containing the hormones) followed by a final sequence of placebo tablets (hormone-free) within the standard 28-day monthly cycle. This combined component drug is classified as an oral contraceptive. The triphasic design is a differentiating factor from monophasic pills, as it was developed to deliver hormone levels that approximate the body's natural cycle.


What is the Primary Purpose of Trivora? (General Benefit)

Trivora is a combination hormonal contraceptive (CHC) taken orally. The drug operates primarily by regulating hormone release to stop ovulation, while simultaneously thickening the cervical mucus and modifying the uterine lining. This dual-hormone mechanism is supported by pharmacological data regarding its biological actions. For a patient group such as women managing their reproductive health, this medication provides an established means of contraception through multiple physiological actions that inhibit the steps required for conception.

Regulatory References

  1. Ethinyl Estradiol and Levonorgestrel (Oral Contraceptives) - MedlinePlus Drug Information
  2. TRIVORA- levonorgestrel and ethinyl estradiol kit - DailyMed

What side effects are possible with Trivora?

Possible Side Effects and Safety Information

This section describes the officially documented safety profile of Trivora (Levonorgestrel and Ethinyl Estradiol Triphasic) as categorized and classified by government regulatory authorities.


Frequency and System Classification

Regulatory documentation groups adverse reactions according to the body system affected and their reported frequency. Common reactions include headache, nausea, abdominal pain, metrorrhagia (irregular bleeding), and breast tenderness. Other documented effects, such as vomiting, weight changes, and changes in mood or libido, are also listed. Effects such as unscheduled bleeding or spotting are noted as being more frequently observed during the start of treatment and the initial cycles of use.


Serious Adverse Reactions

Although rare, official regulatory labels state that the use of combined hormonal contraceptives is associated with the risk of serious adverse reactions. These include Thromboembolic Events, such as deep vein thrombosis, pulmonary embolism (Venous Thromboembolism, VTE), and heart attack or stroke (Arterial Thromboembolism, ATE). The risk of VTE is highest during the first year of use. Other serious risks include the development or worsening of hypertension and the possible occurrence of Hepatic Neoplasms (liver tumors).


Population-Specific Safety Constraints

The product is subject to specific safety restrictions for certain individuals. The medication is contraindicated in women over 35 years of age who smoke, as this combination substantially increases the risk of serious cardiovascular events. It is also contraindicated during known or suspected pregnancy and in individuals with a history of certain vascular diseases or impaired liver function, as defined by the official labeling.

Overdose and Emergency Response

Acute overdose involving combined hormonal contraceptives like Trivora (Levonorgestrel/Ethinyl Estradiol) is documented in regulatory sources as an event with low acute systemic toxicity. Official information indicates that serious or life-threatening outcomes from the acute exposure are considered very unlikely.

The expected clinical presentation following overdose primarily involves transient hormonal manifestations. Regulator-documented signs may include nausea and vomiting, headache, breast tenderness, and drowsiness. A population-specific consideration for females of reproductive potential is the occurrence of vaginal bleeding (or withdrawal bleeding), which may be heavy and typically begins within a week after the overdose.

Despite the low toxicity profile, official labeling strictly mandates that immediate action be taken for any suspected overdose. Patients are required to seek immediate medical attention and contact a Poison Control center right away for necessary clinical guidance and observation. Treatment is formally limited to symptomatic and supportive measures, as no specific antidote is known to reverse the effects of the active components.

Therapeutic Uses of Trivora

Trivora is commonly used in situations involving certain distressing symptoms across two therapeutic domains: fertility control and the symptomatic management of various menstrual cycle-related disorders. This medication is applied across domains where additional symptomatic support is utilized within the category of combined hormonal contraceptives.

Planned Pregnancy Prevention (Contraception)

The primary indication is fertility control. It is considered relevant as an established method of birth control for women of reproductive potential. The medication is applied across domains where management of reproduction is needed, which may assist with maintaining functional stability and generally supports patients in their long-term family planning.


Symptom Management and Cycle Support

Trivora is relevant for easing symptoms that cluster into patterns requiring management, such as promoting cycle predictability. It is utilized to address heavy menstrual bleeding (menorrhagia), menstrual pain (dysmenorrhea), and hormone-related acne. This supportive relief contributes to easing the overall symptom load during difficult episodes.

“It is commonly used to help with symptom clusters that may become intense or disruptive, and is relevant for easing symptoms within the domains of reproductive control and cycle regularity.”

Use Classification: Addressing Menstrual Discomfort

Trivora may assist with managing symptoms associated with recurrent or episodic manifestations, providing supportive relief when symptoms interfere with routine activities caused by unpredictable and intense periods.

Eligibility and Restrictions for Use

This medication is approved for use in females of reproductive potential. However, official regulatory documents state that it is contraindicated (must not be used) in numerous populations, primarily due to an increased risk of serious adverse events.

Populations Who Must Not Use Trivora (Contraindicated)

Exclusion Domain Specific Conditions (Examples)
Thrombotic Risk History of or current deep-vein thrombosis, pulmonary embolism, stroke, heart attack, or thrombogenic valvular disorders.
Smoking and Age Women over 35 years of age who smoke cigarettes.
Malignancy Risk Known or suspected breast cancer or other estrogen- or progestin-dependent cancers.
Hepatic Impairment Liver tumors (benign or malignant), active liver disease, or unrecovered liver function.
Pregnancy/Bleeding Known or suspected pregnancy or undiagnosed abnormal genital bleeding.

Additional Restrictions: Use is also contraindicated in women with uncontrolled hypertension, diabetes with vascular involvement, or those taking specific Hepatitis C drug combinations. The drug should be discontinued before and after major surgery or delivery in non-breastfeeding women due to the risk of thromboembolism. Use is not recommended for females who are breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Trivora is defined by documented substance combinations that are either strictly prohibited or result in modified systemic exposure of the active hormones, Levonorgestrel and Ethinyl Estradiol.

Contraindicated Combinations and Restrictions

Co-administration is formally contraindicated with certain Hepatitis C (HCV) drug regimens, specifically combinations containing Ombitasvir/Paritaprevir/Ritonavir, with or without Dasabuvir. Use is also restricted and contraindicated in females 35 years of age or older who smoke, a condition documented to significantly increase the risk of serious cardiovascular events.

Pharmacokinetic and Pharmacodynamic Interactions

Interactions primarily involve the modulation of metabolic clearance. Strong metabolic enzyme inducers—such as the anticonvulsants Carbamazepine and Phenytoin, the antibiotic Rifampin, and the herbal product St. John’s Wort—are documented to increase the metabolic clearance of the hormones, potentially resulting in reduced systemic exposure. Conversely, strong enzyme inhibitors or other agents (e.g., Atorvastatin, Ascorbic Acid) may increase the systemic exposure of the hormone components. A timing-based restriction is documented for Colesevelam, which must be administered at least four hours after Trivora to mitigate decreased absorption of the contraceptive hormones. Furthermore, pharmacodynamic interactions are documented to decrease the therapeutic effect of anticoagulants.

Mechanism of Action

Central Suppression of the Reproductive Cycle

Trivora operates through a multi-layered mechanism involving the synthetic hormones, Ethinyl Estradiol and Levonorgestrel, to inhibit the physiological processes required for conception. The primary action involves both hormones acting as agonists at their respective receptors within the hypothalamus and pituitary gland. This receptor activation initiates a negative feedback signal to the Hypothalamic-Pituitary-Ovarian (HPO) axis, which suppresses the release of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). This blockade prevents the necessary mid-cycle LH surge, resulting in anovulation (the lack of egg release).

Peripheral Barrier and Tissue Modification

The Levonorgestrel component reinforces the mechanism through actions on the reproductive tract tissues. It acts to increase the thickness and viscosity of the cervical mucus, creating a physical impediment that limits sperm penetration. Concurrently, it causes structural alterations to the endometrium (uterine lining), rendering the environment physiologically unsuitable for early pregnancy processes. This combination establishes three distinct, complementary barriers.

Dosage and Administration Information

How Trivora is Used: Administration Overview

Trivora is an oral triphasic combined contraceptive administered in a structured, sequential 28-day regimen. The medication consists of 21 active hormone tablets followed by 7 hormone-free (inactive) tablets, designed to be taken continuously.

Administration Scope

Parameter Administration Details
Route of Administration Oral (taken by mouth).
Dosing Schedule One tablet daily for 28 consecutive days, starting with the 21 active tablets followed by 7 inactive tablets, sequentially.
Timing in relation to meals Preferably taken after the evening meal or at bedtime.
Age-group rules Indicated for women of reproductive potential. Safety and efficacy profiles are consistent for postpubertal adolescents and adult women.

Procedural Structure and Constraints

The course of treatment involves adherence to a fixed pattern of administration:

  • Fixed Daily Timing: Tablets are taken at the same time each day and administered in the specific order directed on the blister pack to follow the triphasic hormone sequencing.
  • Starting Protocols: Administration begins with the first active tablet on either Day 1 (first day of menses) or the first Sunday after the menstrual period begins.
  • Sequential Use: The three phases of active tablets (containing varying doses of levonorgestrel and ethinyl estradiol) are completed before the final seven inactive tablets are taken.

This continuous, sequential administration pattern is intended to maintain the daily hormone dose throughout the 28-day cycle.

Recent Clinical Evidence

Trivora: Recent Clinical Evidence

Research regarding combination oral contraceptives, including triphasic regimens like Trivora, focuses primarily on efficacy in preventing pregnancy and monitoring safety profiles over time. Trivora contains a sequential dosage of two hormones, ethinyl estradiol and levonorgestrel, across three active phases, designed to closely imitate the natural menstrual cycle.


Efficacy and Contraceptive Outcomes

Studies investigating the effectiveness of combined oral contraceptives (COCs) typically report outcomes using the Pearl Index, which measures the number of pregnancies per 100 woman-years of use. Clinical trials have demonstrated the effectiveness of triphasic COCs in preventing pregnancy when taken as prescribed. The triphasic approach is also studied for its influence on cycle control, with research examining the potential for reduced breakthrough bleeding compared to earlier, higher-dose contraceptive formulations.


Safety and Tolerability Profile

Clinical research highlights the importance of patient screening for potential risks before initiating use of any COC. A significant body of evidence shows that the use of combined oral contraceptives, especially those containing higher estrogen doses (over 50 mu g), is associated with an increased relative risk of venous thromboembolism (VTE), which includes deep-vein thrombosis and pulmonary embolism. Current clinical practice involves the use of lower-dose estrogen formulations to help mitigate this risk.

Common adverse events documented in trials of similar triphasic formulations include:

System Frequently Reported Events
General Headache, Nausea, Vomiting
Reproductive Breast tenderness, Irregular/Heavy Vaginal Bleeding
Other Weight change, Acne

For adult patients who do not smoke and do not have pre-existing cardiovascular risk factors, studies suggest the health benefits of using COCs for fertility control generally outweigh the potential risks.

Frequently Asked Questions (FAQ)

Common questions about Trivora (FAQ)

Q: Is it normal to feel a bit nauseous when taking Trivora?

According to the official product information, nausea and vomiting are listed among the most frequent adverse reactions reported for this type of medication. The experience of nausea is often reported during the initial cycles of use.


Q: Does Trivora cause changes in mood or weight for many users?

Regulatory documents state that changes in weight and changes in mood, such as depression, are documented adverse reactions associated with the use of combination oral contraceptives. These are effects that some users may experience, and they are noted in the product's official safety profile.


Q: Is it true that Trivora can affect my cholesterol levels?

Official warnings state that the use of this medication should be monitored carefully in women with hyperlipidemias (high cholesterol or fats in the blood). This is because some progestogen components may be associated with changes in 'bad' cholesterol (LDL) levels.


Q: Why do official documents emphasize blood pressure monitoring while on Trivora?

Official documents emphasize monitoring due to the documented association between this class of medicine and the risk of hypertension (high blood pressure). Regulatory documents advise that a physical examination for users should include special reference to and periodic checks on blood pressure.


Q: Is it normal to have some breakthrough bleeding when on Trivora?

Official information indicates that unscheduled bleeding or spotting is a commonly reported effect, particularly during the first few cycles or when a user is starting treatment with Trivora. This is noted in the product's adverse reaction profile.


Q: How is Trivora different from other medicines that treat the same condition?

Trivora is identified as a triphasic combination of two hormones. This means its structure is designed to deliver hormone levels sequentially across three active phases, aiming to more closely approximate the body’s natural cycle. This is a key structural difference from monophasic products.


Q: Why does the packaging for Trivora have different color pills?

The different colors are used to distinguish the specific hormone sequence and dose or the hormone-free phase. The colors help indicate the three different active phases (which contain varying amounts of the hormones) and the final inactive, or placebo, tablets.


Q: Are there specific vitamins or supplements that should not be taken with Trivora?

Official product information lists certain substances that may interact. For example, the herbal product St. John’s Wort and vitamins like Ascorbic Acid (Vitamin C) are listed because they may affect the concentration or effectiveness of the hormones in Trivora.


Q: Is there a list of foods or drinks to avoid while taking Trivora?

One known interaction involves certain food products. Grapefruit juice is documented as a food product that may interact by increasing the systemic concentrations of one of the active components of the medication.


Q: How long does it usually take to notice the intended effects of Trivora?

Official prescribing information indicates that contraceptive reliance is generally established only after the first 7 consecutive days of administration. The need for a backup method during this period is a separate administration consideration outlined in the official use protocols.


Q: Does Trivora keep working even if I miss a dose occasionally?

Decreased systemic exposure of the hormones, which can occur from missed doses, may potentially diminish contraceptive effectiveness. This may also be associated with an increase in breakthrough bleeding.


Q: Is Trivora studied in or intended for use by men?

The product is indicated only for use by females of reproductive potential to prevent pregnancy. It is not indicated for or studied in use by men.


Q: What does the research say about the long-term use of Trivora?

Research and regulatory warnings focus on monitoring certain long-term risks associated with this class of medication. These risks include the potential for Thromboembolic Events (blood clots) and effects on Hepatic Neoplasms (liver tumors). Regular monitoring is advised to manage these documented risks.


Q: How might Trivora affect my regular menstrual cycle?

Official documents note that this type of oral contraceptive may contribute to more regular periods. This effect is a common outcome associated with the administration of combination hormonal contraceptives.


Q: Is Trivora the same as Tri-Legest or other similar-sounding names?

Trivora contains the same active drug components—levonorgestrel and ethinyl estradiol—as other similar-sounding triphasic combination oral contraceptives. These products are known as pharmaceutical analogues because they share the same components and structure.


Q: If I have a history of migraines, is Trivora generally appropriate?

Official information notes that this product is contraindicated in those with a history of cerebral-vascular disease (stroke or circulation issues in the brain). This contraindication is related to a history of cerebral-vascular disease, a condition sometimes associated with certain types of migraines.


Q: What happens if I take another medicine that reduces the effect of Trivora?

Co-administration with certain drugs can increase the rate at which the body clears the hormones. This may diminish the contraceptive effectiveness of Trivora and could potentially result in an increase in breakthrough bleeding.


Q: Can Trivora be taken on an empty stomach?

The drug may be taken either with or without food. However, official administration guidelines frequently note that taking it after the evening meal or at bedtime may influence the user experience.


Q: Are there any known issues with alcohol consumption while using Trivora?

Alcohol (ethanol) is noted in drug interaction profiles as a substance that may have a minor interaction with the ethinyl estradiol component. This is noted in official product safety information.


Q: Is Trivora a common cause of acne or other skin changes?

Acne is listed among the adverse reactions frequently reported in clinical trials of similar triphasic formulations. It is included in the official safety profile as a documented skin change.


Q: Why is it important to tell my doctor about all medications I take, even herbals, when starting Trivora?

The disclosure is important because certain other medications, including herbals, can increase the clearance of the hormones. This action may diminish the contraceptive effectiveness of Trivora, which is the reason official product information requests a full disclosure of all products.

How should Trivora be stored and disposed of?

The official requirements for storing and disposing of Trivora (levonorgestrel and ethinyl estradiol tablets) are strictly defined by regulatory documents to ensure product stability and safety. The drug must be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F). Temporary temperature excursions are permitted between 15 C and 30 C (59 F and 86 F). The medication must be protected from excessive heat and excessive moisture and should be maintained in its original packaging configuration.

Storage Requirements

Condition Specification
Temperature Controlled Room Temperature (20 C to 25 C)
Protection Guard from excessive heat and moisture
Child Safety Store out of the reach of children

Disposal Requirements

Unused or expired Trivora must be disposed of according to local and national pharmaceutical waste guidelines. This often involves using designated drug take-back programs or authorized collection points. Disposal via household wastewater, such as flushing down a toilet, is advised against by regulatory bodies for this product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trivora found in:

A-Z Index: